Share This Page
Drugs in ATC Class S01AX
✉ Email this page to a colleague
Up to Top Level ATC Classes
Up to S - Sensory organs
Up to S01 - OPHTHALMOLOGICALS
Up to S01A - ANTIINFECTIVES
Drugs in ATC Class: S01AX - Other antiinfectives
| Tradename | Generic Name |
|---|---|
| AVAGARD | alcohol; chlorhexidine gluconate |
| EXIDINE | chlorhexidine gluconate |
| CHLORHEXIDINE GLUCONATE | chlorhexidine gluconate |
| READYPREP CHG | chlorhexidine gluconate |
| PAROEX | chlorhexidine gluconate |
| >Tradename | >Generic Name |
ATC Class S01AX “Other Antiinfectives” Market Dynamics and Patent Landscape (2026)
Executive summary: ATC S01AX (other antiinfectives) is a fragmented, brand-light class where revenue is driven by individual, molecule-specific IP estates rather than by broad platform monopolies. Patent protection is typically split across (1) active ingredient processes, (2) salt/ester/polymorph or prodrug variants where relevant, (3) ophthalmic formulation systems (viscosity control, pH and buffering, preservatives, osmolarity, droplet-size and comfort), and (4) method-of-use claims (infectious keratitis, blepharitis, conjunctivitis, prophylaxis around ocular surgery). Exclusivity timing is often determined by whether filings are tied to NCE approvals versus only to formulation/device changes, which shifts the balance between “strong NDA-holder estates” and “fast generic follow-on” risk. In practice, generic and biosimilar timelines are less central than Paragraph IV dynamics for reformulated ophthalmics and the extent to which an NDA’s Orange Book listings include formulation and method-of-use patents that block 505(b)(2) and ANDA work.
Net effect: For investors and licensors, the key question inside S01AX is not “How many patents exist in the class,” but “Which specific drug(s) within S01AX have Orange Book coverage for formulation and/or method-of-use that survives until the intended generic launch date,” plus whether litigation (often settled) has delayed approval.
Which drugs fall under ATC S01AX “Other antiinfectives,” and how does that shape the patent landscape?
Featured snippet answer: S01AX is not a single mechanism class; it is an aggregation bucket in the ATC system. Patent coverage therefore tracks the specific ophthalmic anti-infective products included in S01AX rather than a unified patent strategy.
What is the S01AX scope in practice?
S01AX includes ophthalmic antiinfectives that do not fit into other ATC ophthalmic antiinfective subcategories. Business impact:
- Portfolio breadth is wide, but each member has a small- to mid-sized revenue footprint versus major glaucoma or anti-VEGF categories.
- Patent estates tend to be local to each active ingredient and route of administration (ocular drops, ointments, suspensions, gels).
How ATC bucket structure affects freedom-to-operate
- Label-driven method-of-use claims: ophthalmic indications often expand across related infections (keratitis versus blepharitis), allowing newer filings to capture additional sub-indications even when the active ingredient is older.
- Formulation dominance: preservatives, buffering, viscosity agents, and solubilizers can create distinct patentable compositions even for legacy antibiotics.
- Process patents: less visible in Orange Book listings if not tied to NDA manufacturing or if the holder does not list them for Orange Book purposes.
How strong is the patent estate for ophthalmic “other antiinfectives” in S01AX?
Featured snippet answer: Strength is molecule- and dossier-specific. Estates tend to be strongest when holders list formulation and method-of-use patents in the Orange Book and litigate under Paragraph IV or 505(b)(2) carveouts.
Common patent layers seen in S01AX-style ophthalmic estates
- Composition-of-matter or prodrug/salt claims
- Strongest where the active ingredient is newer or where a specific ophthalmic-compatible derivative is protected.
- Formulation patents
- Buffer system, pH window, tonicity agents, viscosity agents, chelators, surfactants.
- Suspension stabilization for poorly soluble drugs is a frequent claim target.
- Method-of-use claims
- Treatment regimens (dose frequency), duration, and patient subpopulations (post-surgical prophylaxis, contact lens-related infections, resistant organism coverage).
- Manufacturing/process patents
- Jet-milling, sterilization, aseptic fill processes, particle-size control, and container closure system.
What determines “blocking power” against generics?
- Whether patents are listed in the FDA’s Orange Book for the specific NDA/BLA or are held in reserve but not listed.
- Whether claims are enforceable against ANDA formulations and whether a generic can “design around” formulation limitations.
- Whether the holder obtained early exclusivity (NCE, new formulation NDA approvals) that extends beyond the last patent.
When does patent exclusivity end for S01AX ophthalmic products, and what delays matter most?
Featured snippet answer: In this class, the exclusivity timeline is usually governed by the intersection of (1) FDA regulatory exclusivities (where applicable) and (2) last Orange Book-listed patent expirations, with delay from litigation settlements and consent decrees.
Exclusivity timing: the practical model
- Regulatory exclusivity (drug-specific): often shorter in ophthalmics unless tied to NCE and new clinical data.
- Patent expiry: often the true gating item, especially for formulation and method-of-use.
- Hatch-Waxman litigation: can shift generic approval by years even when exclusivity is not maximal.
What to track in each S01AX member product
- Orange Book “Drug Patent Information” listings for the relevant NDA.
- Expiration dates for listed patents (composition, formulation, method).
- Whether patents are “earliest effective” for generic launch decisions due to “blocking” listings.
- Litigation docket dates if Paragraph IV has been filed.
What patents protect ophthalmic “other antiinfectives” formulations in S01AX?
Featured snippet answer: The most blocking patents are typically formulation patents that specify buffering, pH/tonicity, viscosity and preservative systems, stabilization of suspensions, and sometimes container closure attributes.
Formulation claim clusters seen in ophthalmic antiinfectives
- Aqueous drops vs suspensions
- Particle size distribution or suspension stability claims are common for older antibiotics with solubility constraints.
- pH and buffering
- Specific buffer species and concentration ranges that maintain stability and ocular tolerability.
- Tonicity agents
- Sodium chloride and alternative tonicity control systems to prevent stinging while maintaining stability.
- Viscosity and comfort
- Mucoadhesive agents, viscosity modifiers, and surfactants used for retention and reduced ocular discomfort.
- Preservative systems
- Benzalkonium chloride alternatives or reduced preservative technologies, often used to justify newer patents.
Design-around feasibility
- If Orange Book listings are limited to narrow pH or preservative specifications, generics can seek non-infringing compositions.
- If claims cover broader formulation ranges or multiple dependent claims, design-around may require additional studies and slow 505(b)(2) strategies.
Which method-of-use patents cover S01AX infectious indications, and how do they affect generic launches?
Featured snippet answer: Method-of-use patents that tie dose regimen and indication to an approved label are among the most effective barriers in ophthalmic antiinfectives.
Indication and regimen patterns
- Keratitis and corneal infection
- Specific dosing frequency and duration windows.
- Blepharitis and meibomian gland-related infections
- Adjunctive regimens, eyelid hygiene combinations, and frequency-driven protocols.
- Conjunctivitis
- Rapid onset dosing schedules and organism-target specificity.
- Postoperative prophylaxis
- Dosing around cataract or other ocular surgeries.
Litigation consequence
- If a patent is method-of-use blocking and the generic seeks an aligned label, it often triggers Paragraph IV and litigation.
- If the generic can file a narrower label by omitting the patented regimen/indication, entry timing can improve but market uptake may be constrained.
What Orange Book status applies to S01AX ophthalmic antiinfectives?
Featured snippet answer: Orange Book coverage varies widely by product; the class does not behave like a uniform monopoly. Many legacy antibiotics have few listed patents by now, while newer reformulations often have multiple formulation patents still in force.
How to interpret Orange Book for this class
- Narrow number of listed patents suggests lower barrier and faster 505(b)(2)/ANDA entry.
- Multiple formulation and method patents suggest an estate structured for longer tail protection, often paired with settlement-based delay.
Operational takeaway for market entrants
- The cost-benefit of Paragraph IV hinges on whether the ANDA applicant can carve out labeled indications or design around formulation limitations without triggering clinical bridging burdens.
How many Paragraph IV challenges exist for S01AX “other antiinfectives,” and what patterns do they follow?
Featured snippet answer: In practice, S01AX Paragraph IV activity is less frequent than in high-volume systemic antibiotics, but where it occurs it clusters around ophthalmic reformulations with Orange Book-listed formulation or method-of-use patents.
Typical Paragraph IV triggers
- A generic seeks approval for an ophthalmic product with a close formulation to the reference listed drug.
- The applicant challenges one or more listed patents as invalid and/or not infringed.
- Litigation frequently ends in a settlement with delayed launch or agreed carveouts.
Settlement-driven delay
- Even when the last patent expiry is far out, settlements often create predictable launch windows.
- The commercial implication is to price risk based on the settlement structure, not just the theoretical patent expiry.
Which companies are most active in challenging or defending S01AX ophthalmic antiinfective patents?
Featured snippet answer: Activity is typically concentrated among generic and ophthalmic-focused specialty developers for challenges, and brand holders with mature portfolios for defense; the most relevant players are molecule-specific rather than category-wide.
Who tends to be active
- ANDA applicants with ophthalmic experience: tend to pursue 505(b)(2) or ANDA pathways once listed patents are mapped.
- Brand holders: tend to defend with claim-scope narrowing strategies and settlement leverage.
What to measure
- History of settlements for the same NDA portfolio.
- Volume of Orange Book listings per NDA as a proxy for legal complexity.
How does S01AX patent risk compare across delivery forms: drops, suspensions, and ointments?
Featured snippet answer: Drops and suspensions often have more formulation-driven patent layers because stability, viscosity, and comfort drive distinct claim sets. Ointments can have fewer formulation differences but may have stronger container closure or rheology claim coverage.
Risk mechanics by dosage form
- Suspensions
- Particle-size and stabilization claims can make infringement analyses technical.
- Drops
- Preservative and pH/buffer system patents can block faster “same actives, new bottle” strategies.
- Ointments
- Rheology and base composition can be a design-around bottleneck, but fewer generics may pursue them if market size is smaller.
What generic entry risks exist for S01AX ophthalmic antiinfectives under 505(b)(2) and ANDA?
Featured snippet answer: The primary risks are Orange Book blocking patents tied to formulation and method-of-use, and the possibility that carveouts reduce label value enough to weaken commercial viability.
Entry pathway differences
- ANDA
- Often used when a pathway can certify around listed patents or wait out expiry.
- 505(b)(2)
- Can enable design around by relying on literature and bridging studies, but formulation patents and method-of-use claims can still drive litigation.
Commercial viability risks
- Even with regulatory approval, claims carveouts may force a narrower label than the reference product.
- For ophthalmics, reduced indication breadth can directly hit patient volume.
What manufacturing/IP barriers matter for S01AX ophthalmic antiinfectives?
Featured snippet answer: The largest IP barriers are often not the active ingredient, but the manufacturing controls that preserve stability and sterility across a shelf life and patient-use timeframe.
Barrier clusters
- Aseptic fill validation and container closure compatibility
- Particle-size and suspension stability controls
- Preservative system stability across storage and opening cycles
- Sterilization and filtration parameters that impact particle agglomeration
Key Takeaways
- S01AX is fragmented. Patent strategy and exclusivity timing are molecule-specific and formulation-driven rather than category-wide.
- Formulation and method-of-use patents are the main blockers. Where Orange Book listings include pH/buffer/viscosity/preservative details or labeled dosing regimens, generic entry risk rises.
- Litigation and settlements drive real timelines. For products with multiple listed patents, Paragraph IV challenges can create multi-year entry delay even when some claims are weak.
- Dose form changes matter legally. Suspension stability and drop comfort formulation patents typically create higher infringement complexity than simple reconstitution.
- For market entry, map Orange Book first. Commercial viability depends on whether the applicant can maintain a competitive label without infringing blocking patents.
FAQs
- How do Orange Book “blocking” patents for ophthalmic antiinfectives influence 505(b)(2) design-around strategies?
- What claim types (composition, formulation, method-of-use) most often drive ANDA litigation in ophthalmic antiinfectives?
- How should investors evaluate the difference between last patent expiry and actual settlement-based generic entry timing?
- Which dosage forms in ophthalmology tend to have the most formulation patent density and why?
- How can a label carveout around a method-of-use patent change expected revenue for an S01AX generic?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. FDA. Hatch-Waxman Amendments and Paragraph IV certifications. FDA guidance and resources.
More… ↓
